U.S. Food and Drug Administration, Center for Drug Evaluation and Research

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Écoutez des podcasts informatifs sur les traitements du cancer, les approbations de produits et les mises à jour de sécurité en oncologie et développement de médicaments.

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

3 mins • Jan 17, 2025

Charts

146
NEW
Apple Podcasts – Royaume-Uni – Médecine
116
NEW
Apple Podcasts – Australie – Médecine
172
Decreased by 45
Apple Podcasts – Japon – Médecine
118
Decreased by 22
Apple Podcasts – Suède – Médecine
199
Decreased by 6
Apple Podcasts – Ghana – Médecine

Épisodes récents

Jan 17, 2025

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

3 mins

Dec 30, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

3 mins

Nov 18, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

3 mins

Nov 14, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

4 mins

Aug 16, 2024

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer

5 mins

Langue

Anglais

Pays

États-Unis

Catégories

Site web

Flux

Demander une mise à jour

Les mises à jour peuvent prendre quelques minutes.

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

Charts

Apple Podcasts – Royaume-Uni – Médecine

Apple Podcasts – Australie – Médecine

Apple Podcasts – Japon – Médecine

Apple Podcasts – Suède – Médecine

Apple Podcasts – Ghana – Médecine

Épisodes récents

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer